A Prospective Clinical Trial to Evaluate Mesothelin as a Biomarker for the Clinical Management of Esophageal Cancer

Protocol
11-037
Full Title
A Prospective Clinical Trial to Establish Mesothelin as a Biomarker for the Clinical Management of Barrett's Esophagus and Esophageal Adenocarcinoma (EAC)
Purpose

The purpose of this study is to find out whether a protein called mesothelin, which is found in the blood and tissue, can be used as “marker” for esophageal cancer. Investigators are comparing levels of this protein between patients with abnormal esophageal cells or tissue and patients being treated for esophageal cancer. They will see how mesothelin levels correlate with the stage of disease, a patient’s response to treatment, and the risk of recurrence. Doctor hope to identify a marker such as mesothelin that can help guide them in making treatment decisions for their patients.

Eligibility

This study includes patients with stage I-III adenocarcinoma of the esophagus who are age 18 or older and are being treated at Memorial Sloan-Kettering Cancer Center.

For more information about this study, please contact Dr. Nabil Rizk or Research Coordinators Alain Vincent or Amanda Ghanie at 212-639-8357.

Disease(s)
Esophageal Disorders: Barrett's Esophagus
Upper Gastrointestinal: Esophageal Cancer
Locations
Related Diseases

Cancer Clinical Trials: Personalizing for Each Patient

Join our experts for a discussion of clinical trials on November 18. Clinical trials can give patients access to new drugs and other treatments before they are widely available, but how do you know if a trial is right for you?

Learn more »